Status:
WITHDRAWN
Adoptive Immunotherapy for CMV Disease
Lead Sponsor:
Hadassah Medical Organization
Conditions:
CMV Disease
Eligibility:
All Genders
Phase:
PHASE1
PHASE2
Brief Summary
Treatment strategy of patients: Stem cell engraftment (myeloablative or NST) for induction of host vs graft myeloablative transplantation tolerance. Whenever indicated, additional post NST DLI given...
Eligibility Criteria
Inclusion
- For Patient:
- Consenting patients with indication for myeloablative BMT or NST with an HLA matching sibling available, for transplant.
- Patients at risk of CMV disease including seronegative patients; patients with seronegative donors, and seronegative donor for sero positive patients.
- Patients with resistant CMV viremia or CMV disease not responding to conventional treatment with ganciclovir, or Foscarnet.
- Patients with HLA phenotype for which a relevant peptide for CMV exists.
- For Donor:
- Consenting sibling \>18 years old.
- HLA phenotype for which a relevant peptide for CMV exists.
Exclusion
- For Patient:
- Patients with severe resistant GVHD where there may be a risk to administer DLI or immunized donor lymphocytes.
- For Donor:
- Consenting sibling \>18 years old.
- HLA phenotype for which a relevant peptide for CMV exists.
- Donor with an infectious disease (e.g. HIV-1; HBV, etc.)
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00159055
Start Date
February 1 2004
Last Update
April 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel, 91120